GLP-1 use is safe and effective with many pre-existing conditions with the exception of the following: Currently pregnant Currently breastfeeding Currently being treated for cancer Active eating disorder Active gallbladder disease Active substance abuse or dependency Type 1 diabetes Bariatric surgery (within the past 18 months) Pancreatitis within the past 6 months, or a history of pancreatitis caused by taking a GLP-1 Personal or family history of medullary thyroid cancer or MEN syndrome Personal history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
The two are used together: ipamorelin prompts a growth-hormone pulse and CJC-1295 extends it, making the combination more potent than either compound alone
Current evidence supports the safety profile of GLP-1 medications when prescribed appropriately, with benefits in glycaemic control and cardiovascular risk reduction generally outweighing theoretical thyroid concerns for most patients
(Medications that alter blood sugar can have various effects on vision and should be evaluated promptly by an eye doctor.) Mass or swelling in the neck
Call to see our current offerings and see how peptide therapies can help you start your weight loss journey today
(1) By binding to GLP-1 receptors, Semaglutide: Enhances insulin secretion Suppresses glucagon release (which reduces blood sugar levels) Delays gastric emptying Promotes satiety These combined actions have been shown to help regulate blood sugar levels and reduce appetite
,aspect=ignore)
,aspect=ignore)
